In several malignant entities, including melanoma, prostate cancer, pancreatic cancer, lung cancer and glioma, oncogenic RAS/MAPK signaling has been identified as an enhancer of transcriptional activation and function of GLI [93,95,96,97,98,99]. Here, GLI1 is linked to melanoma.